AtaiBeckley CMO exercises options, sells shares
AtaiBeckley Inc.’s Chief Medical Officer, Craig Kevin James, reported an option exercise-and-sale transaction in company stock.
Rhea-AI Filing Summary
AtaiBeckley Inc.’s Chief Medical Officer, Craig Kevin James, reported an option exercise-and-sale transaction in company stock. On June 25, 2026, he exercised stock options covering 42,579 shares of common stock at strike prices of $1.18 and $1.50 per share and sold 42,579 shares in open-market transactions at a weighted average price of $4.51 per share. The filing states these option exercises and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025. After the transactions, he held 8,437 shares of common stock directly and continued to hold stock options, including 28,608 options at an exercise price of $1.18 expiring on March 14, 2033 and 673,808 options at an exercise price of $1.50 expiring on March 3, 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 33,051 | $0.00 | $0.00 |
| Exercise | Stock Option | 9,528 | $0.00 | $0.00 |
| Exercise | Common Stock | 33,051 | $1.50 | $50K |
| Exercise | Common Stock | 9,528 | $1.18 | $11K |
| Sale | Common Stock | 42,579 | $4.51 | $192K |
Footnotes (4)
- F1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
- F2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.50 to $4.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
- F3. The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
- F4. The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter.
Key Figures
Key Terms
Rule 10b5-1 trading plan financial
weighted average price financial
stock option financial
substantially equal monthly installments financial
derivative security financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did AtaiBeckley (ATAI) report for Craig Kevin James?
Was the AtaiBeckley CMO’s ATAI stock sale under a Rule 10b5-1 plan?
What stock options in AtaiBeckley (ATAI) does the CMO still own after exercising some?
AI-generated analysis. How Rhea-AI works. Not financial advice.